Topiramate

  • 1 lab in 1 country
  • Funder: Indian Council of Medical Research
  • Human trial1

Outcomes

1

QRISK3

upin humans1

1 study
  1. Topiramate improves QRISK3 in humans (MD = 0.61 (0.02 to 1.21)).

    Human trialin patients of schizophrenia with metabolic syndrome on atypical antipsychotics50 mg/dayeight weeks

    Efficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trial

    European archives of psychiatry and clinical neuroscience4 Aug 2026

More on QRISK3

Latest

Nov 2025: 2Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 03 in 12 months